nodes	percent_of_prediction	percent_of_DWPC	metapath
Etomidate—CYP19A1—uterine cancer	0.787	1	CbGaD
Etomidate—CYP19A1—corpus luteum—uterine cancer	0.0194	0.248	CbGeAlD
Etomidate—CYP19A1—semen—uterine cancer	0.00909	0.116	CbGeAlD
Etomidate—SLC2A1—epithelium—uterine cancer	0.00529	0.0677	CbGeAlD
Etomidate—SLC2A1—decidua—uterine cancer	0.005	0.064	CbGeAlD
Etomidate—SLC2A1—renal system—uterine cancer	0.00491	0.0628	CbGeAlD
Etomidate—SLC2A1—mammalian vulva—uterine cancer	0.00459	0.0587	CbGeAlD
Etomidate—SLC2A1—uterus—uterine cancer	0.00437	0.056	CbGeAlD
Etomidate—CYP11B2—renal system—uterine cancer	0.0042	0.0538	CbGeAlD
Etomidate—SLC2A1—female reproductive system—uterine cancer	0.00393	0.0503	CbGeAlD
Etomidate—SLC2A1—female gonad—uterine cancer	0.00358	0.0458	CbGeAlD
Etomidate—SLC2A1—vagina—uterine cancer	0.00356	0.0455	CbGeAlD
Etomidate—SLC2A1—lymph node—uterine cancer	0.0023	0.0294	CbGeAlD
Etomidate—CYP11B2—lymph node—uterine cancer	0.00197	0.0252	CbGeAlD
Etomidate—CYP19A1—endometrium—uterine cancer	0.0015	0.0192	CbGeAlD
Etomidate—CYP19A1—uterus—uterine cancer	0.00138	0.0177	CbGeAlD
Etomidate—CYP19A1—female reproductive system—uterine cancer	0.00124	0.0159	CbGeAlD
Etomidate—CYP19A1—female gonad—uterine cancer	0.00113	0.0145	CbGeAlD
Etomidate—CYP11B2—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000795	0.00599	CbGpPWpGaD
Etomidate—SLC2A1—Insulin Signaling—IGF1R—uterine cancer	0.000745	0.00561	CbGpPWpGaD
Etomidate—CYP19A1—lymph node—uterine cancer	0.000727	0.0093	CbGeAlD
Etomidate—CYP11B2—Metapathway biotransformation—AKR1C1—uterine cancer	0.000695	0.00523	CbGpPWpGaD
Etomidate—SLC2A1—HIF-1-alpha transcription factor network—EP300—uterine cancer	0.000693	0.00522	CbGpPWpGaD
Etomidate—CYP11B1—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000685	0.00516	CbGpPWpGaD
Etomidate—SLC2A1—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.00067	0.00504	CbGpPWpGaD
Etomidate—SLC2A1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	0.000656	0.00494	CbGpPWpGaD
Etomidate—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000651	0.0049	CbGpPWpGaD
Etomidate—CYP19A1—Ovarian Infertility Genes—SMAD3—uterine cancer	0.000648	0.00488	CbGpPWpGaD
Etomidate—CYP19A1—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000643	0.00484	CbGpPWpGaD
Etomidate—CYP11B2—Metapathway biotransformation—GPX3—uterine cancer	0.00061	0.00459	CbGpPWpGaD
Etomidate—SLC2A1—Validated targets of C-MYC transcriptional activation—EP300—uterine cancer	0.0006	0.00452	CbGpPWpGaD
Etomidate—CYP11B1—Metapathway biotransformation—AKR1C1—uterine cancer	0.000599	0.00451	CbGpPWpGaD
Etomidate—CYP11B2—Biological oxidations—CYP11A1—uterine cancer	0.000574	0.00432	CbGpPWpGaD
Etomidate—CYP11B2—Metapathway biotransformation—CYP11A1—uterine cancer	0.000566	0.00426	CbGpPWpGaD
Etomidate—CYP11B2—Metapathway biotransformation—AKR1C3—uterine cancer	0.000535	0.00403	CbGpPWpGaD
Etomidate—CYP19A1—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000528	0.00397	CbGpPWpGaD
Etomidate—CYP11B1—Metapathway biotransformation—GPX3—uterine cancer	0.000526	0.00396	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.00051	0.00384	CbGpPWpGaD
Etomidate—CYP19A1—Metapathway biotransformation—AKR1B10—uterine cancer	0.000497	0.00374	CbGpPWpGaD
Etomidate—CYP11B1—Biological oxidations—CYP11A1—uterine cancer	0.000495	0.00373	CbGpPWpGaD
Etomidate—CYP11B1—Metapathway biotransformation—CYP11A1—uterine cancer	0.000488	0.00367	CbGpPWpGaD
Etomidate—CYP19A1—Metapathway biotransformation—AKR1B1—uterine cancer	0.000462	0.00348	CbGpPWpGaD
Etomidate—CYP11B1—Metapathway biotransformation—AKR1C3—uterine cancer	0.000461	0.00347	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000439	0.00331	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—NDUFB11—uterine cancer	0.000434	0.00327	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—SRD5A2—uterine cancer	0.000434	0.00327	CbGpPWpGaD
Etomidate—SLC2A1—Validated targets of C-MYC transcriptional activation—TP53—uterine cancer	0.00043	0.00323	CbGpPWpGaD
Etomidate—CYP11B2—Biological oxidations—CYP19A1—uterine cancer	0.000423	0.00318	CbGpPWpGaD
Etomidate—SLC2A1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	0.000419	0.00315	CbGpPWpGaD
Etomidate—CYP11B2—Metapathway biotransformation—CYP19A1—uterine cancer	0.000417	0.00314	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—MSH6—uterine cancer	0.000413	0.00311	CbGpPWpGaD
Etomidate—SLC2A1—Disease—AKR1B10—uterine cancer	0.000403	0.00303	CbGpPWpGaD
Etomidate—GABRB2—Neuronal System—ABCC9—uterine cancer	0.000376	0.00283	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000369	0.00277	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000369	0.00277	CbGpPWpGaD
Etomidate—CYP11B1—Biological oxidations—CYP19A1—uterine cancer	0.000364	0.00274	CbGpPWpGaD
Etomidate—CYP19A1—Ovarian Infertility Genes—CDKN1B—uterine cancer	0.00036	0.00271	CbGpPWpGaD
Etomidate—CYP11B1—Metapathway biotransformation—CYP19A1—uterine cancer	0.000359	0.0027	CbGpPWpGaD
Etomidate—SLC2A1—Insulin Signaling—PTEN—uterine cancer	0.000358	0.00269	CbGpPWpGaD
Etomidate—GABRG2—Neuronal System—ABCC9—uterine cancer	0.000344	0.00259	CbGpPWpGaD
Etomidate—CYP19A1—Metapathway biotransformation—AKR1C1—uterine cancer	0.000339	0.00255	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—MSH2—uterine cancer	0.000335	0.00252	CbGpPWpGaD
Etomidate—SLC2A1—Disease—RNF43—uterine cancer	0.000334	0.00251	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000318	0.00239	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000318	0.00239	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—STAR—uterine cancer	0.000314	0.00236	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—AKR1B1—uterine cancer	0.000314	0.00236	CbGpPWpGaD
Etomidate—GABRA1—Neuronal System—ABCC9—uterine cancer	0.000301	0.00226	CbGpPWpGaD
Etomidate—CYP19A1—Metapathway biotransformation—GPX3—uterine cancer	0.000298	0.00224	CbGpPWpGaD
Etomidate—CYP19A1—Biological oxidations—CYP11A1—uterine cancer	0.00028	0.00211	CbGpPWpGaD
Etomidate—CYP11B1—Corticotropin-releasing hormone—CXCL8—uterine cancer	0.000279	0.0021	CbGpPWpGaD
Etomidate—CYP19A1—Metapathway biotransformation—CYP11A1—uterine cancer	0.000277	0.00208	CbGpPWpGaD
Etomidate—SLC2A1—Disease—AKR1C1—uterine cancer	0.000275	0.00207	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000271	0.00204	CbGpPWpGaD
Etomidate—CYP19A1—Metapathway biotransformation—AKR1C3—uterine cancer	0.000261	0.00197	CbGpPWpGaD
Etomidate—CYP11B1—Corticotropin-releasing hormone—CTNNB1—uterine cancer	0.000258	0.00194	CbGpPWpGaD
Etomidate—SLC2A1—Insulin Signaling—PIK3CA—uterine cancer	0.000252	0.0019	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—YWHAE—uterine cancer	0.000251	0.00189	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000249	0.00187	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—POLD1—uterine cancer	0.000246	0.00185	CbGpPWpGaD
Etomidate—Myoclonus—Medroxyprogesterone Acetate—uterine cancer	0.000242	0.108	CcSEcCtD
Etomidate—SLC2A1—Disease—DCN—uterine cancer	0.000238	0.00179	CbGpPWpGaD
Etomidate—SLC2A1—Insulin Signaling—HRAS—uterine cancer	0.000234	0.00176	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000233	0.00176	CbGpPWpGaD
Etomidate—Hyperventilation—Progesterone—uterine cancer	0.000233	0.104	CcSEcCtD
Etomidate—GABRA1—SIDS Susceptibility Pathways—ESR2—uterine cancer	0.000232	0.00175	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—AKR1C1—uterine cancer	0.00023	0.00173	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—STK11—uterine cancer	0.000229	0.00172	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—NDUFB11—uterine cancer	0.000227	0.00171	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—SRD5A2—uterine cancer	0.000227	0.00171	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000221	0.00166	CbGpPWpGaD
Etomidate—CYP19A1—FSH signaling pathway—AKT1—uterine cancer	0.000219	0.00165	CbGpPWpGaD
Etomidate—SLC2A1—Disease—AKR1C3—uterine cancer	0.000212	0.00159	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000208	0.00157	CbGpPWpGaD
Etomidate—SLC2A1—Disease—HMGA1—uterine cancer	0.000206	0.00155	CbGpPWpGaD
Etomidate—SLC2A1—Insulin Signaling—AKT1—uterine cancer	0.000206	0.00155	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—RRM2—uterine cancer	0.000205	0.00155	CbGpPWpGaD
Etomidate—GABRB2—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000202	0.00152	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—DCN—uterine cancer	0.000199	0.0015	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—NDUFB11—uterine cancer	0.000196	0.00147	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—SRD5A2—uterine cancer	0.000196	0.00147	CbGpPWpGaD
Etomidate—Laryngospasm—Medroxyprogesterone Acetate—uterine cancer	0.000195	0.0867	CcSEcCtD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.00019	0.00143	CbGpPWpGaD
Etomidate—SLC2A1—Disease—FBXW7—uterine cancer	0.000189	0.00142	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—CYP11A1—uterine cancer	0.000188	0.00141	CbGpPWpGaD
Etomidate—GABRG2—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000185	0.00139	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.00018	0.00136	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.00018	0.00136	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000179	0.00135	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—AKR1C3—uterine cancer	0.000177	0.00134	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—AKR1B1—uterine cancer	0.000164	0.00124	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—STAR—uterine cancer	0.000164	0.00124	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	0.000162	0.00122	CbGpPWpGaD
Etomidate—GABRA1—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000162	0.00122	CbGpPWpGaD
Etomidate—ADRA2B—Platelet Aggregation (Plug Formation)—AKT1—uterine cancer	0.000153	0.00116	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—ESR1—uterine cancer	0.000153	0.00115	CbGpPWpGaD
Etomidate—SLC2A1—Disease—CDKN2B—uterine cancer	0.000148	0.00111	CbGpPWpGaD
Etomidate—CYP11B1—Corticotropin-releasing hormone—AKT1—uterine cancer	0.000145	0.00109	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—AKR1B1—uterine cancer	0.000141	0.00106	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—STAR—uterine cancer	0.000141	0.00106	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	0.00014	0.00105	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—STK11—uterine cancer	0.000138	0.00104	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—CYP19A1—uterine cancer	0.000138	0.00104	CbGpPWpGaD
Etomidate—SLC2A1—Disease—SMAD3—uterine cancer	0.000135	0.00102	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—CDH1—uterine cancer	0.000133	0.001	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000132	0.000995	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—POLD1—uterine cancer	0.000129	0.00097	CbGpPWpGaD
Etomidate—SLC2A1—Disease—FGFR2—uterine cancer	0.000129	0.00097	CbGpPWpGaD
Etomidate—SLC2A1—Disease—MTHFR—uterine cancer	0.000124	0.000933	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—AKR1C1—uterine cancer	0.00012	0.000907	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—POLD1—uterine cancer	0.000111	0.000836	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—SRD5A2—uterine cancer	0.000111	0.000835	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—NDUFB11—uterine cancer	0.000111	0.000835	CbGpPWpGaD
Etomidate—Laryngospasm—Etoposide—uterine cancer	0.00011	0.049	CcSEcCtD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000108	0.000811	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—RRM2—uterine cancer	0.000107	0.000808	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—DCN—uterine cancer	0.000104	0.000785	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—MTHFR—uterine cancer	0.000104	0.000782	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—AKR1C1—uterine cancer	0.000104	0.000782	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000102	0.000766	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—IRF1—uterine cancer	0.0001	0.000755	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—CTNNB1—uterine cancer	9.82e-05	0.000739	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—CYP11A1—uterine cancer	9.82e-05	0.000739	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—CXCL8—uterine cancer	9.79e-05	0.000737	CbGpPWpGaD
Etomidate—Apnoea—Etoposide—uterine cancer	9.68e-05	0.0431	CcSEcCtD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—PTEN—uterine cancer	9.57e-05	0.000721	CbGpPWpGaD
Etomidate—Pain—Carboplatin—uterine cancer	9.31e-05	0.0415	CcSEcCtD
Etomidate—CYP11B2—Metabolism—AKR1C3—uterine cancer	9.27e-05	0.000698	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—RRM2—uterine cancer	9.25e-05	0.000697	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—EP300—uterine cancer	9.13e-05	0.000687	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	9.04e-05	0.00068	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—DCN—uterine cancer	8.98e-05	0.000676	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—uterine cancer	8.65e-05	0.000651	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—CYP11A1—uterine cancer	8.46e-05	0.000637	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—EP300—uterine cancer	8.4e-05	0.000632	CbGpPWpGaD
Etomidate—SLC2A1—Disease—ERBB2—uterine cancer	8.09e-05	0.000609	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—AKR1B1—uterine cancer	8.02e-05	0.000603	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—STAR—uterine cancer	8.02e-05	0.000603	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—AKR1C3—uterine cancer	7.99e-05	0.000602	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—VEGFA—uterine cancer	7.96e-05	0.000599	CbGpPWpGaD
Etomidate—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	7.84e-05	0.00059	CbGpPWpGaD
Etomidate—SLC2A1—Disease—CDKN1B—uterine cancer	7.49e-05	0.000564	CbGpPWpGaD
Etomidate—Bradycardia—Medroxyprogesterone Acetate—uterine cancer	7.43e-05	0.0331	CcSEcCtD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—KRAS—uterine cancer	7.35e-05	0.000553	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—STK11—uterine cancer	7.23e-05	0.000544	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—CYP19A1—uterine cancer	7.23e-05	0.000544	CbGpPWpGaD
Etomidate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	7.17e-05	0.00054	CbGpPWpGaD
Etomidate—SLC2A1—Disease—CTNNB1—uterine cancer	7.08e-05	0.000533	CbGpPWpGaD
Etomidate—SLC2A1—Disease—PTEN—uterine cancer	6.9e-05	0.000519	CbGpPWpGaD
Etomidate—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	6.79e-05	0.000511	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.78e-05	0.000511	CbGpPWpGaD
Etomidate—ADRA2B—G alpha (i) signalling events—CXCL8—uterine cancer	6.75e-05	0.000508	CbGpPWpGaD
Etomidate—Hyperventilation—Epirubicin—uterine cancer	6.68e-05	0.0298	CcSEcCtD
Etomidate—SLC2A1—Disease—EP300—uterine cancer	6.58e-05	0.000495	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—TP53—uterine cancer	6.53e-05	0.000492	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—AKR1B10—uterine cancer	6.51e-05	0.00049	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.47e-05	0.000487	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—POLD1—uterine cancer	6.29e-05	0.000474	CbGpPWpGaD
Etomidate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	6.27e-05	0.000472	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—STK11—uterine cancer	6.23e-05	0.000469	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—CYP19A1—uterine cancer	6.23e-05	0.000469	CbGpPWpGaD
Etomidate—Hyperventilation—Doxorubicin—uterine cancer	6.18e-05	0.0275	CcSEcCtD
Etomidate—SLC2A1—Disease—NRAS—uterine cancer	6.15e-05	0.000463	CbGpPWpGaD
Etomidate—Convulsion—Progesterone—uterine cancer	6.07e-05	0.0271	CcSEcCtD
Etomidate—Hypertension—Progesterone—uterine cancer	6.05e-05	0.027	CcSEcCtD
Etomidate—GABRB2—Transmission across Chemical Synapses—HRAS—uterine cancer	5.89e-05	0.000444	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—AKR1C1—uterine cancer	5.88e-05	0.000443	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.84e-05	0.00044	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—PTEN—uterine cancer	5.78e-05	0.000435	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	5.76e-05	0.000433	CbGpPWpGaD
Etomidate—Tachycardia—Progesterone—uterine cancer	5.58e-05	0.0249	CcSEcCtD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.57e-05	0.00042	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—AKT1—uterine cancer	5.52e-05	0.000415	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—EP300—uterine cancer	5.51e-05	0.000415	CbGpPWpGaD
Etomidate—Convulsion—Medroxyprogesterone Acetate—uterine cancer	5.5e-05	0.0245	CcSEcCtD
Etomidate—CYP11B2—Metabolism—MTHFR—uterine cancer	5.43e-05	0.000409	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—RNF43—uterine cancer	5.39e-05	0.000406	CbGpPWpGaD
Etomidate—GABRG2—Transmission across Chemical Synapses—HRAS—uterine cancer	5.39e-05	0.000406	CbGpPWpGaD
Etomidate—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	5.36e-05	0.000404	CbGpPWpGaD
Etomidate—Hypotension—Progesterone—uterine cancer	5.35e-05	0.0238	CcSEcCtD
Etomidate—SLC2A1—Disease—KRAS—uterine cancer	5.3e-05	0.000399	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—RRM2—uterine cancer	5.24e-05	0.000395	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—CCL2—uterine cancer	5.17e-05	0.000389	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—DCN—uterine cancer	5.09e-05	0.000383	CbGpPWpGaD
Etomidate—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	5.06e-05	0.0225	CcSEcCtD
Etomidate—ADRA2B—Signaling Pathways—INHBA—uterine cancer	4.93e-05	0.000371	CbGpPWpGaD
Etomidate—Pain—Progesterone—uterine cancer	4.89e-05	0.0218	CcSEcCtD
Etomidate—SLC2A1—Disease—PIK3CA—uterine cancer	4.87e-05	0.000366	CbGpPWpGaD
Etomidate—Hypotension—Medroxyprogesterone Acetate—uterine cancer	4.84e-05	0.0216	CcSEcCtD
Etomidate—CYP19A1—Metabolism—CYP11A1—uterine cancer	4.8e-05	0.000361	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.78e-05	0.00036	CbGpPWpGaD
Etomidate—GABRA1—Transmission across Chemical Synapses—HRAS—uterine cancer	4.71e-05	0.000355	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—MTHFR—uterine cancer	4.68e-05	0.000352	CbGpPWpGaD
Etomidate—Hiccups—Epirubicin—uterine cancer	4.6e-05	0.0205	CcSEcCtD
Etomidate—CYP19A1—Metabolism—AKR1C3—uterine cancer	4.53e-05	0.000341	CbGpPWpGaD
Etomidate—GABRB2—Neuronal System—HRAS—uterine cancer	4.52e-05	0.00034	CbGpPWpGaD
Etomidate—SLC2A1—Disease—HRAS—uterine cancer	4.5e-05	0.000339	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	4.5e-05	0.000338	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—AKR1C1—uterine cancer	4.44e-05	0.000334	CbGpPWpGaD
Etomidate—Hiccups—Doxorubicin—uterine cancer	4.26e-05	0.019	CcSEcCtD
Etomidate—GABRG2—Neuronal System—HRAS—uterine cancer	4.13e-05	0.000311	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.12e-05	0.00031	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—CXCL8—uterine cancer	4.09e-05	0.000308	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—PIK3CA—uterine cancer	4.07e-05	0.000307	CbGpPWpGaD
Etomidate—SLC2A1—Disease—AKT1—uterine cancer	3.97e-05	0.000299	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—AKT1—uterine cancer	3.67e-05	0.000276	CbGpPWpGaD
Etomidate—Vomiting—Progesterone—uterine cancer	3.64e-05	0.0162	CcSEcCtD
Etomidate—GABRA1—Neuronal System—HRAS—uterine cancer	3.61e-05	0.000272	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—STK11—uterine cancer	3.53e-05	0.000266	CbGpPWpGaD
Etomidate—Pain—Dactinomycin—uterine cancer	3.46e-05	0.0154	CcSEcCtD
Etomidate—ADRA2B—Signaling Pathways—AKR1C3—uterine cancer	3.42e-05	0.000257	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PGR—uterine cancer	3.33e-05	0.000251	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—AKT1—uterine cancer	3.33e-05	0.000251	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.31e-05	0.000249	CbGpPWpGaD
Etomidate—Vomiting—Medroxyprogesterone Acetate—uterine cancer	3.3e-05	0.0147	CcSEcCtD
Etomidate—ADRA2B—Signaling Pathways—YWHAE—uterine cancer	3.18e-05	0.000239	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.16e-05	0.000238	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—EP300—uterine cancer	3.13e-05	0.000236	CbGpPWpGaD
Etomidate—Convulsion—Etoposide—uterine cancer	3.11e-05	0.0138	CcSEcCtD
Etomidate—Hypertension—Etoposide—uterine cancer	3.1e-05	0.0138	CcSEcCtD
Etomidate—ADRA2B—Signaling Pathways—FBXW7—uterine cancer	3.05e-05	0.000229	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PTEN—uterine cancer	3.02e-05	0.000227	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—VEGFA—uterine cancer	2.97e-05	0.000223	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—NRAS—uterine cancer	2.93e-05	0.000221	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—EP300—uterine cancer	2.88e-05	0.000217	CbGpPWpGaD
Etomidate—Tachycardia—Etoposide—uterine cancer	2.86e-05	0.0127	CcSEcCtD
Etomidate—Hypotension—Etoposide—uterine cancer	2.74e-05	0.0122	CcSEcCtD
Etomidate—ADRA2B—Signaling Pathways—STK11—uterine cancer	2.66e-05	0.000201	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—MTHFR—uterine cancer	2.65e-05	0.0002	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—CCL2—uterine cancer	2.65e-05	0.0002	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PTEN—uterine cancer	2.6e-05	0.000196	CbGpPWpGaD
Etomidate—Vomiting—Dactinomycin—uterine cancer	2.57e-05	0.0115	CcSEcCtD
Etomidate—ADRA2B—Hemostasis—KRAS—uterine cancer	2.52e-05	0.00019	CbGpPWpGaD
Etomidate—Pain—Etoposide—uterine cancer	2.5e-05	0.0111	CcSEcCtD
Etomidate—ADRA2B—Signaling Pathways—SOCS3—uterine cancer	2.49e-05	0.000188	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—EP300—uterine cancer	2.48e-05	0.000187	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CDKN2B—uterine cancer	2.39e-05	0.00018	CbGpPWpGaD
Etomidate—Bradycardia—Epirubicin—uterine cancer	2.35e-05	0.0105	CcSEcCtD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.34e-05	0.000176	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—IGF1R—uterine cancer	2.32e-05	0.000175	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—PIK3CA—uterine cancer	2.32e-05	0.000174	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—CXCL8—uterine cancer	2.31e-05	0.000174	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—TP53—uterine cancer	2.24e-05	0.000169	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—SMAD3—uterine cancer	2.18e-05	0.000164	CbGpPWpGaD
Etomidate—Bradycardia—Doxorubicin—uterine cancer	2.18e-05	0.00969	CcSEcCtD
Etomidate—ADRA2B—Hemostasis—HRAS—uterine cancer	2.14e-05	0.000161	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PIK3CA—uterine cancer	2.13e-05	0.00016	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—CXCL8—uterine cancer	2.1e-05	0.000158	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—FGFR2—uterine cancer	2.08e-05	0.000157	CbGpPWpGaD
Etomidate—Arrhythmia—Epirubicin—uterine cancer	2.06e-05	0.00919	CcSEcCtD
Etomidate—Arrhythmia—Doxorubicin—uterine cancer	1.91e-05	0.0085	CcSEcCtD
Etomidate—ADRA2B—Hemostasis—AKT1—uterine cancer	1.89e-05	0.000143	CbGpPWpGaD
Etomidate—Vomiting—Etoposide—uterine cancer	1.86e-05	0.00829	CcSEcCtD
Etomidate—CYP11B1—Metabolism—PIK3CA—uterine cancer	1.84e-05	0.000138	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—ESR1—uterine cancer	1.78e-05	0.000134	CbGpPWpGaD
Etomidate—Convulsion—Epirubicin—uterine cancer	1.74e-05	0.00776	CcSEcCtD
Etomidate—CYP11B2—Metabolism—AKT1—uterine cancer	1.74e-05	0.000131	CbGpPWpGaD
Etomidate—Hypertension—Epirubicin—uterine cancer	1.74e-05	0.00773	CcSEcCtD
Etomidate—ADRA2B—Signaling by GPCR—NRAS—uterine cancer	1.68e-05	0.000127	CbGpPWpGaD
Etomidate—Convulsion—Doxorubicin—uterine cancer	1.61e-05	0.00718	CcSEcCtD
Etomidate—Hypertension—Doxorubicin—uterine cancer	1.61e-05	0.00715	CcSEcCtD
Etomidate—Tachycardia—Epirubicin—uterine cancer	1.6e-05	0.00713	CcSEcCtD
Etomidate—ADRA2B—Signaling Pathways—CCL2—uterine cancer	1.57e-05	0.000118	CbGpPWpGaD
Etomidate—Hypotension—Epirubicin—uterine cancer	1.53e-05	0.00683	CcSEcCtD
Etomidate—CYP11B1—Metabolism—AKT1—uterine cancer	1.5e-05	0.000113	CbGpPWpGaD
Etomidate—Tachycardia—Doxorubicin—uterine cancer	1.48e-05	0.0066	CcSEcCtD
Etomidate—CYP19A1—Metabolism—PTEN—uterine cancer	1.48e-05	0.000111	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—PIK3CA—uterine cancer	1.46e-05	0.00011	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—KRAS—uterine cancer	1.45e-05	0.000109	CbGpPWpGaD
Etomidate—Hypotension—Doxorubicin—uterine cancer	1.42e-05	0.00632	CcSEcCtD
Etomidate—CYP19A1—Metabolism—EP300—uterine cancer	1.41e-05	0.000106	CbGpPWpGaD
Etomidate—Pain—Epirubicin—uterine cancer	1.4e-05	0.00625	CcSEcCtD
Etomidate—ADRA2B—Signaling by GPCR—PIK3CA—uterine cancer	1.33e-05	0.0001	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—ERBB2—uterine cancer	1.31e-05	9.83e-05	CbGpPWpGaD
Etomidate—Pain—Doxorubicin—uterine cancer	1.3e-05	0.00578	CcSEcCtD
Etomidate—ADRA2B—Signaling Pathways—CXCL8—uterine cancer	1.24e-05	9.32e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—HRAS—uterine cancer	1.23e-05	9.26e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CDKN1B—uterine cancer	1.21e-05	9.1e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—AKT1—uterine cancer	1.2e-05	9.01e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CTNNB1—uterine cancer	1.14e-05	8.6e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PTEN—uterine cancer	1.11e-05	8.38e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—AKT1—uterine cancer	1.09e-05	8.18e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—EP300—uterine cancer	1.06e-05	8e-05	CbGpPWpGaD
Etomidate—Vomiting—Epirubicin—uterine cancer	1.04e-05	0.00465	CcSEcCtD
Etomidate—CYP19A1—Metabolism—PIK3CA—uterine cancer	1.04e-05	7.83e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—VEGFA—uterine cancer	1.01e-05	7.57e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—NRAS—uterine cancer	9.94e-06	7.48e-05	CbGpPWpGaD
Etomidate—Vomiting—Doxorubicin—uterine cancer	9.65e-06	0.0043	CcSEcCtD
Etomidate—ADRA2B—Signaling Pathways—KRAS—uterine cancer	8.55e-06	6.44e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—AKT1—uterine cancer	8.5e-06	6.4e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PIK3CA—uterine cancer	7.86e-06	5.91e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—TP53—uterine cancer	7.6e-06	5.72e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—HRAS—uterine cancer	7.27e-06	5.47e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—AKT1—uterine cancer	6.42e-06	4.83e-05	CbGpPWpGaD
